Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Chandrawati, Lily
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Role of Gut Microbiota Dysbiosis as a Potential Factor in Early Diagnosis, Prognosis and Therapeutic Strategy of COVID-19 Patients Tandarto, Kevin; Suyandi, Kadek Ari; Chandrawati, Lily
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 24, No 3 (2023): VOLUME 24, NUMBER 3, December, 2023
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/2432023242

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the most widespread global pandemic since the 1918 influenza pandemic. The consequences of the coronavirus disease 2019 (COVID-19) are devastating and become the current world major public health issue. Not only SARS-CoV-2 attack the respiratory system, but also can affect multiple organs. Clinical manifestation varies from asymptomatic to severe multiorgan dysfunctions. COVID-19 is typically associated with a set of comorbidities such as hypertension, diabetes, obesity, and/or advanced age, which significantly exacerbates the consequences of infection. During the early stages of the disease, SARS-CoV-2 can also cause gastrointestinal symptoms such as vomiting, diarrhea, or abdominal pain. Intestinal dysfunction alters intestinal microbes and increases inflammatory cytokines. As a result, diagnosing gastrointestinal symptoms that procede respiratory problems during COVID-19 infection may be required for better early diagnosis and treatment. Discovering the composition of the microbiota and its metabolic products in the context of COVID-19 can aid in the identification of novel disease biomarkers and therapeutic targets. In the context of COVID-19, elucidating changes to the microbiome as reliable biomarkers represents an overlooked piece of the disease puzzle that requires further investigation.
Challenges and Gaps in the Management of Chronic Hepatitis C Infection: Insight from A Tertiary Hospital in Indonesia Chandrawati, Lily; Permatadewi, Cecilia Octaria; Hutami, Hesti Triwahyu; Indiarso, Didik; Purnomo, Hery Djagat
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 27, No 1 (2026): VOLUME 27, NUMBER 1, April, 2026
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/271202645-50

Abstract

Background: Hepatitis C virus (HCV) infection remains a significant public health burden in Indonesia, affecting approximately 2.5 million people. The introduction of direct-acting antivirals (DAAs) has revolutionized HCV management by offering highly effective and well-tolerated treatment options. Since 2017, Indonesia has implemented an HCV cascade of care and a government-funded DAA program to support the World Health Organization (WHO) goal of HCV elimination by 2030. However, challenges in diagnostic accessibility and treatment follow-up continue to hamper progress. This study aims to evaluate the implementation of the HCV cascade of care at Dr. Kariadi General Hospital, Semarang, Indonesia.Methods: A retrospective descriptive study was conducted at Dr. Kariadi General Hospital, which included data from patients who tested positive for anti-HCV antibodies between January 2019 and November 2024. HCV treatment was categorized into five stages: (1) positive anti-HCV antibody test, (2) HCV RNA test, (3) positive HCV RNA result, (4) treatment initiation, and (5) sustained virologic response 12 weeks post-treatment (SVR12). Data analysis was performed using SPSS Statistics version 26. Categorical variables were expressed as frequencies and percentages, and findings were presented as numbers and proportions across each stage of the care cascade.Results: Among 317 patients with positive anti-HCV antibody results (55% men, 45% women; median age: 56 years), 280 (88%) underwent HCV RNA testing, and 213 (76%) were confirmed positive. Of these, 185 patients (87%) initiated treatment, 144 (78%) completed therapy, and 108 (75%) achieved SVR12.Conclusion: This study shows that significant gaps remain at various stages of the HCV care cascade, particularly in confirmatory HCV RNA testing, treatment initiation, and post-treatment follow-up.
Co-Authors Didik Indiarso Hery Djagat Purnomo Hutami, Hesti Triwahyu I Dewa Nyoman Wibawa Permatadewi, Cecilia Octaria Suyandi, Kadek Ari Tandarto, Kevin